This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rigel Announces Initiation Of Clinical Trials In Two Immunology Programs

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL: Nasdaq) today announced that two of its lead product candidates entered clinical trials during the fourth quarter of 2011. The company is evaluating R548, an oral JAK3 inhibitor, as a potential therapeutic for transplant rejection and other systemic immune disorders. The second candidate, R333, is a topical JAK/SYK inhibitor aimed at treating various phases of discoid lupus (lupus of the skin). Rigel's product pipeline will be the focus of the company's presentation at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9th at 1:30 pm Pacific Time (webcast details below).

"Rigel continues to be one of the most productive companies in the biopharmaceutical sector, as evidenced by the commencement of First in Human (FIH) studies in two programs this past quarter," said James M. Gower, chairman and chief executive officer of Rigel. "The goal of our highly-talented 155 person R&D-focused organization is to add at least one new product candidate into the clinic each year for the foreseeable future and move those into proof-of-concept trials. We plan to have Phase 2 trial results in three internal programs in 2013," he added

R548, JAK3 Inhibitor

Transplant rejection is an area of tremendous medical need. While 90% of patients survive the first year after receiving the transplanted organ, chronic organ rejection rates rise to 50% within the five to ten years following surgery. Currently available therapeutics are not sufficient to help these patients achieve lasting recovery. Furthermore, transplants of certain organs are rarely done because of the inadequacies of these therapies. Rigel's R548 is a JAK3 inhibitor that is expected to moderate the immune system's response to the allograft and improve patient outcomes. R548 may also have application in treating other immune system disorders. Phase 1 clinical studies in normal healthy volunteers began in the fourth quarter of 2011.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs